Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sanofi - American Depositary Shares (NQ:SNY)

41.04 -0.19 (-0.46%)
Delayed Quote Updated: 11:45 AM EDT, Oct 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,987,493
Open 41.85
Bid (Size) 41.03 (300)
Ask (Size) 41.06 (1,200)
Prev. Close 41.23
Today's Range 40.82 - 41.88
52wk Range 40.40 - 52.68
Shares Outstanding 1,250,690,553
Dividend Yield 5.90%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Sanofi, Regeneron Expand DUPIXENT Alliance in Deal Worth Up to €8 Billion ↗
Regeneron and Sanofi (NASDAQ:SNY) announced an expanded collaboration focused on developing next-generation medicines for type 2 inflammatory diseases, extending an alliance that has produced the... 
Via MarketBeat
News headline image
Regeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology Antibodies
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire

Performance

YTD
-14.9%
-14.9%
1 Month
-7.5%
-7.5%
3 Month
-1.4%
-1.4%
6 Month
-14.0%
-14.0%
1 Year
-13.1%
-13.1%

More News

Read More
News headline image
Is Regeneron Stock a Bargain Below $800? ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Sanofi Reviews Pipeline, Broadens Deal Hunt as It Rebuilds Research Engine ↗
Via MarketBeat
Sanofi-ADR (NASDAQ:SNY): A Dividend Quality Candidate with Solid Profitability ↗
Via Chartmill
Sanofi (NASDAQ:SNY) Screens as Undervalued Value Stock with Solid Profitability ↗
Via Chartmill
Sanofi-ADR (NASDAQ:SNY) Offers a High Dividend Yield With Strong Underlying Quality ↗
Via Chartmill
News headline image
Sanofi Eyes €25B Dupixent Future, Expands M&A Hunt Ahead of Patent Loss ↗
Via MarketBeat
Topics Intellectual Property
A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach
Via Investor Brand Network
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Gains Editorial Spotlight Following FDA Clearance for Lucid-MS Phase 2 Trial
Via Investor Brand Network
SANOFI-ADR (NASDAQ:SNY): A Decent Value Stock With Strong Fundamentals and an Undervalued Profile ↗
Via Chartmill
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Gains Editorial Spotlight Following FDA Clearance for Lucid-MS Phase 2 Trial
Via Investor Brand Network
MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Gains Editorial Spotlight Following FDA Clearance for Lucid-MS Phase 2 Trial
Via Investor Brand Network
News headline image
A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach
From BioMedWire
Via GlobeNewswire
News headline image
Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now? ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Sanofi Boasts a Dividend Yield of 5.4%, Trades Below 9x Earnings, and Just Got an FDA Win. Are Income Investors Missing a Rare Opportunity? ↗
Via The Motley Fool
News headline image
Sanofi Q2 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
News headline image
The Smartest Dividend Stock to Buy With $1,000 Right Now (Spoiler: It Yields 5.6%.) ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Next-Generation Diabetes Therapies Are Reshaping Healthcare and Creating MultiBillion-Dollar Revenue Opportunities
Via FinancialNewsMedia
News headline image
3 High-Yield Dividend Stocks to Buy and Hold ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
2 Fast-Growing Pharmaceutical Stocks to Buy Now ↗
Via The Motley Fool
News headline image
Bargain Hunters: These 3 High-Yielding Stocks Recently Hit New 52-Week Lows ↗
Via The Motley Fool
Topics Intellectual Property
MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Novel Multiple Sclerosis Therapy Toward Phase 2 Trials
Via Investor Brand Network
Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis
Via Investor Brand Network
News headline image
Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis
From BioMedWire
Via GlobeNewswire

Frequently Asked Questions

Is Sanofi - American Depositary Shares publicly traded?
Yes, Sanofi - American Depositary Shares is publicly traded.
What exchange does Sanofi - American Depositary Shares trade on?
Sanofi - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Sanofi - American Depositary Shares?
The ticker symbol for Sanofi - American Depositary Shares is SNY on the Nasdaq Stock Market
What is the current price of Sanofi - American Depositary Shares?
The current price of Sanofi - American Depositary Shares is 41.04
When was Sanofi - American Depositary Shares last traded?
The last trade of Sanofi - American Depositary Shares was at 10/01/26 11:45 AM ET
What is the market capitalization of Sanofi - American Depositary Shares?
The market capitalization of Sanofi - American Depositary Shares is 51.33B
How many shares of Sanofi - American Depositary Shares are outstanding?
Sanofi - American Depositary Shares has 51B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.